IL18BP and renal cell carcinoma: To determine if these findings extended beyond the TME, we quantified circulating plasma levels of IL-18BP using ELISA in patients with RCC before and after treatment with ipilimumab and nivolumab (ipi + nivo) in the frontline setting (Supplemental Table 4).